Albert C M Ong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5847025/publications.pdf

Version: 2024-02-01

169	6,824	57758	69250
papers	citations	44 h-index	77 g-index

260	260	260	6229
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 1524-1528.	7.1	239
2	Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet, The, 2015, 385, 1993-2002.	13.7	227
3	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 2016, 31, 337-348.	0.7	206
4	Molecular pathogenesis of ADPKD: The polycystin complex gets complex. Kidney International, 2005, 67, 1234-1247.	5.2	202
5	Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet, The, 2003, 361, 2196-2201.	13.7	198
6	Fabrication and Luminescence of Monolayered Boron Nitride Quantum Dots. Small, 2014, 10, 60-65.	10.0	196
7	Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet, The, 2014, 383, 1844-1859.	13.7	194
8	Fabrication of Luminescent Monolayered Tungsten Dichalcogenides Quantum Dots with Giant Spin-Valley Coupling. ACS Nano, 2013, 7, 8214-8223.	14.6	181
9	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv15-iv25.	0.7	180
10	Identification, Characterization, and Localization of a Novel Kidney Polycystin-1-Polycystin-2 Complex. Journal of Biological Chemistry, 2002, 277, 20763-20773.	3.4	178
11	Coordinate Expression of the Autosomal Dominant Polycystic Kidney Disease Proteins, Polycystin-2 And Polycystin-1, in Normal and Cystic Tissue. American Journal of Pathology, 1999, 154, 1721-1729.	3.8	174
12	Structural and molecular basis of the assembly of the TRPP2/PKD1 complex. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11558-11563.	7.1	163
13	A polycystin-centric view of cyst formation and disease: the polycystins revisited. Kidney International, 2015, 88, 699-710.	5.2	140
14	Polycystic kidney diseaseâ€"the ciliary connection. Lancet, The, 2003, 361, 774-776.	13.7	130
15	Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription factor. Human Molecular Genetics, 2006, 16, 265-275.	2.9	129
16	Involvement of Hypoxia-Inducible Transcription Factors in Polycystic Kidney Disease. American Journal of Pathology, 2007, 170, 830-842.	3.8	118
17	Loss of glomerular function and tubulointerstitial fibrosis:Cause or effect?. Kidney International, 1994, 45, 345-351.	5.2	111
18	The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin. Clinical Endocrinology, 1991, 34, 43-49.	2.4	101

#	Article	IF	Citations
19	Identification of Mutations in the Duplicated Region of the Polycystic Kidney Disease 1 Gene (PKD1) by a Novel Approach. American Journal of Human Genetics, 1997, 60, 1399-1410.	6.2	100
20	An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney International, 1995, 48, 390-401.	5.2	99
21	Mechanisms of tubulo-interstitial injury in progressive renal diseases. European Journal of Clinical Investigation, 1993, 23, 259-265.	3.4	94
22	A stable, nonsense mutation associated with a case of infantile onset polycystic kidney disease 1 (PKD1). Human Molecular Genetics, 1996, 5, 539-542.	2.9	94
23	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney International, 2014, 86, 1244-1252.	5.2	91
24	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrology Dialysis Transplantation, 2018, 33, ii4-ii14.	0.7	91
25	Polycystic Kidney Disease Is a Risk Factor for New-Onset Diabetes After Transplantation. Transplantation, 2007, 83, 36-40.	1.0	90
26	Polycystin-1 expression in PKD1, early-onset PKD1, and TSC2/PKD1 cystic tissue. Kidney International, 1999, 56, 1324-1333.	5.2	87
27	Identification of an N-terminal glycogen synthase kinase 3 phosphorylation site which regulates the functional localization of polycystin-2 in vivo and in vitro. Human Molecular Genetics, 2006, 15, 1465-1473.	2.9	83
28	Tubular-Derived Growth Factors and Cytokines in the Pathogenesis of Tubulointerstitial Fibrosis: Implications for Human Renal Disease Progression. American Journal of Kidney Diseases, 1994, 23, 205-209.	1.9	81
29	Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrology Dialysis Transplantation, 2006, 21, 2078-2084.	0.7	78
30	Functional Analysis of PKD1 Transgenic Lines Reveals a Direct Role for Polycystin-1 in Mediating Cell-Cell Adhesion. Journal of the American Society of Nephrology: JASN, 2003, 14, 1804-1815.	6.1	77
31	Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system. Kidney International, 2007, 72, 157-165.	5.2	74
32	Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphatemic osteomalacia. Bone, 1996, 18, 159-169.	2.9	72
33	A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO Journal, 2010, 29, 1176-1191.	7.8	70
34	Imaging of Kidney Cysts and Cystic Kidney Diseases in Children: An International Working Group Consensus Statement. Radiology, 2019, 290, 769-782.	7.3	69
35	Autosomal Dominant Polycystic Kidney Disease: Recent Advances in Pathogenesis and Treatment. Nephron Physiology, 2008, 108, p1-p7.	1.2	63
36	Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. American Journal of Human Genetics, 2022, 109, 136-156.	6.2	62

#	Article	IF	Citations
37	Mechanism-Based Therapeutics for Autosomal Dominant Polycystic Kidney Disease: Recent Progress and Future Prospects. Nephron Clinical Practice, 2012, 120, c25-c35.	2.3	61
38	Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13320-13329.	7.1	54
39	Identification and Functional Characterization of an N-terminal Oligomerization Domain for Polycystin-2. Journal of Biological Chemistry, 2008, 283, 28471-28479.	3.4	50
40	Human high density lipoproteins stimulate endothelin-1 release by cultured human renal proximal tubular cells. Kidney International, 1994, 46, 1315-1321.	5.2	49
41	Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells. Journal of Cell Science, 2009, 122, 1410-1417.	2.0	48
42	Molecular basis of renal cyst formationâ€"one hit or two?. Lancet, The, 1997, 349, 1039-1040.	13.7	47
43	Hyperphosphorylation of polycystin-2 at a critical residue in disease reveals an essential role for polycystin-1-regulated dephosphorylation. Human Molecular Genetics, 2013, 22, 1924-1939.	2.9	47
44	How simple are 'simple renal cysts'?. Nephrology Dialysis Transplantation, 2014, 29, iv106-iv112.	0.7	44
45	Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney International, 2020, 97, 370-382.	5.2	44
46	An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrology Dialysis Transplantation, 2022, 37, 825-839.	0.7	44
47	STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease. Kidney International, 2017, 91, 575-586.	5.2	41
48	Effect of cyclosporin A on endothelin synthesis by cultured human renal cortical epithelial cells. Nephrology Dialysis Transplantation, 1993, 8, 748-753.	0.7	40
49	Aberrant Polycystin-1 Expression Results in Modification of Activator Protein-1 Activity, whereas Wnt Signaling Remains Unaffected. Journal of Biological Chemistry, 2004, 279, 27472-27481.	3.4	40
50	Endothelin B Receptor Blockade Accelerates Disease Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 560-569.	6.1	40
51	Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease. Kidney International, 2020, 98, 420-435.	5.2	40
52	Metabolic abnormalities in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2015, 30, 197-203.	0.7	38
53	Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 1130-1140.	0.7	38
54	Activation of TRPP2 through mDia1-dependent voltage gating. EMBO Journal, 2008, 27, 1345-1356.	7.8	37

#	Article	IF	Citations
55	New treatments for autosomal dominant polycystic kidney disease. British Journal of Clinical Pharmacology, 2013, 76, n/a-n/a.	2.4	37
56	Protein Kinase Dâ€“mediated Phosphorylation of Polycystin-2 (TRPP2) Is Essential for Its Effects on Cell Growth and Calcium Channel Activity. Molecular Biology of the Cell, 2010, 21, 3853-3865.	2.1	36
57	Tubular lipidosis: Epiphenomenon or pathogenetic lesion in human renal disease?. Kidney International, 1994, 45, 753-762.	5.2	34
58	The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 639-646.	0.5	34
59	A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC Nephrology, 2018, 19, 37.	1.8	34
60	Regional Variations in Endothelin-1 and its Receptor Subtypes in Human Coronary Vasculature: Pathophysiological Implications in Coronary Disease. Endothelium: Journal of Endothelial Cell Research, 1998, 6, 61-70.	1.7	32
61	Angiopoietin-1 regulates microvascular reactivity and protects the microcirculation during acute endothelial dysfunction: Role of eNOS and VE-cadherin. Pharmacological Research, 2014, 80, 43-51.	7.1	31
62	Biallelic inheritance of hypomorphic PKD1 variants is highly prevalent in very early onset polycystic kidney disease. Genetics in Medicine, 2021, 23, 689-697.	2.4	31
63	Polycystin Expression in the Kidney and Other Tissues: Complexity, Consensus and Controversy. Nephron Experimental Nephrology, 2000, 8, 208-214.	2.2	30
64	Cosegregation of Focal Segmental Glomerulosclerosis in a Family with Familial Partial Lipodystrophy due to a Mutation in <i>LMNA</i>. Nephron Clinical Practice, 2013, 124, 31-37.	2.3	29
65	The Polycystin-1, Lipoxygenase, and Î±-Toxin Domain Regulates Polycystin-1 Trafficking. Journal of the American Society of Nephrology: JASN, 2016, 27, 1159-1173.	6.1	29
66	Cystic kidney diseases: many ways to form a cyst. Pediatric Nephrology, 2013, 28, 33-49.	1.7	28
67	European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. Nephrology Dialysis Transplantation, 2018, 33, 563-573.	0.7	28
68	Expression and Cellular Localisation of Renal Endothelin-1 and Endothelin Receptor Subtypes in Autosomal-Dominant Polycystic Kidney Disease. Nephron Experimental Nephrology, 2003, 93, e80-e86.	2.2	27
69	Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2018, 33, 1310-1316.	0.7	27
70	An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes. Kidney International, 2020, 98, 1589-1604.	5.2	27
71	Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. BMJ Open, 2020, 10, e032620.	1.9	27
72	Detection of Proximal Tubular Motile Cilia in a Patient With Renal Sarcoidosis Associated With Hypercalcemia. American Journal of Kidney Diseases, 2005, 45, 1096-1099.	1.9	26

#	Article	IF	Citations
73	Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression. American Journal of Physiology - Renal Physiology, 2017, 312, F577-F588.	2.7	26
74	Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H33-H41.	3.2	25
75	The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis inÂvitro is counteracted by increased kidney inflammation inÂvivo. Kidney International, 2020, 98, 404-419.	5.2	25
76	Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review. Renal Failure, 2021, 43, 1-15.	2.1	25
77	Polycystin-1 regulates ARHGAP35-dependent centrosomal RhoA activation and ROCK signaling. JCI Insight, 2020, 5, .	5.0	25
78	The Role of Phospholipase D in Modulating the MTOR Signaling Pathway in Polycystic Kidney Disease. PLoS ONE, 2013, 8, e73173.	2.5	25
79	Atrial natriuretic peptide release responds to atrial stretch and not to atrial pressure: observations during pericardiocentesis in a young woman. European Heart Journal, 1990, 11, 368-371.	2.2	23
80	Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. American Journal of Kidney Diseases, 2020, 76, 361-373.	1.9	23
81	Hypersensitivity vasculitis complicating intravenous streptokinase therapy in acute myocardial infarction. International Journal of Cardiology, 1988, 21, 71-73.	1.7	22
82	A Single Amino Acid Residue Constitutes the Third Dimerization Domain Essential for the Assembly and Function of the Tetrameric Polycystin-2 (TRPP2) Channel. Journal of Biological Chemistry, 2011, 286, 18994-19000.	3.4	22
83	Screening for intracranial aneurysms in ADPKD. BMJ: British Medical Journal, 2009, 339, b3763-b3763.	2.3	21
84	Peroxisome Proliferator-Activated Receptor Gamma Agonists in Kidney Disease â€“ Future Promise, Present Fears. Nephron Clinical Practice, 2009, 112, c230-c241.	2.3	21
85	The cAMP Signaling Pathway and Direct Protein Kinase A Phosphorylation Regulate Polycystin-2 (TRPP2) Channel Function. Journal of Biological Chemistry, 2015, 290, 23888-23896.	3.4	21
86	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€“Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. American Journal of Kidney Diseases, 2021, 77, 255-263.	1.9	21
87	Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin. Pflugers Archiv European Journal of Physiology, 2013, 466, 1591-604.	2.8	20
88	The Sorting Nexin 3 Retromer Pathway Regulates the Cell Surface Localization and Activity of a Wnt-Activated Polycystin Channel Complex. Journal of the American Society of Nephrology: JASN, 2017, 28, 2973-2984.	6.1	20
89	Standardised Outcomes in Nephrologyâ€”Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials, 2017, 18, 560.	1.6	20
90	Identifying patientâ€important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology, 2019, 24, 1214-1224.	1.6	20

#	Article	IF	Citations
91	Polycystin-2 expression is increased following experimental ischaemic renal injury. Nephrology Dialysis Transplantation, 2002, 17, 2138-2144.	0.7	18
92	Genetic Testing in the Assessment of Living Related Kidney Donors at Risk of Autosomal Dominant Polycystic Kidney Disease. Transplantation, 2015, 99, 1023-1029.	1.0	18
93	A high throughput zebrafish chemical screen reveals ALK5 and non-canonical androgen signalling as modulators of the pkd2â^'/â^' phenotype. Scientific Reports, 2020, 10, 72.	3.3	18
94	Autosomal dominant polycystic kidney disease: recent advances in clinical management. F1000Research, 2016, 5, 2029.	1.6	17
95	Sinus arrest and asystole due to severe lithium intoxication. International Journal of Cardiology, 1991, 30, 364-366.	1.7	16
96	Endothelin and Tubulointerstitial Renal Disease. Seminars in Nephrology, 2015, 35, 197-207.	1.6	16
97	A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease. European Radiology, 2019, 29, 4188-4197.	4.5	16
98	Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. American Journal of Kidney Diseases, 2020, 76, 213-223.	1.9	16
99	Tubulointerstitial actions of endothelins in the kidney: roles in health and disease. Nephrology Dialysis Transplantation, 1996, 11, 251-257.	0.7	14
100	Autosomal dominant polycystic kidney disease. Clinical Medicine, 2009, 9, 278-283.	1.9	13
101	The Controversial Role of Fibrosis in Autosomal Dominant Polycystic Kidney Disease. International Journal of Molecular Sciences, 2020, 21, 8936.	4.1	13
102	Endothelin in Polycystic Kidney Disease. Contributions To Nephrology, 2011, 172, 200-209.	1.1	12
103	Primary cilia and renal cysts: does length matter?. Nephrology Dialysis Transplantation, 2013, 28, 2661-2663.	0.7	12
104	Tolvaptan slows disease progression in late-stage ADPKD. Nature Reviews Nephrology, 2018, 14, 146-148.	9.6	12
105	Renal monocyte chemoattractant protein-1: an emerging universal biomarker and therapeutic target for kidney diseases?. Nephrology Dialysis Transplantation, 2020, 35, 198-203.	0.7	12
106	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. Nephrology Dialysis Transplantation, 2014, 29, iv26-iv32.	0.7	11
107	Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2017, 32, 2144-2144.	0.7	11
108	Tuberous Sclerosis Complex (TSC): Expert Recommendations for Provision of Coordinated Care. Frontiers in Neurology, 2019, 10, 1116.	2.4	11

#	Article	IF	Citations
109	Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice. Human Molecular Genetics, 2022, 31, 1560-1573.	2.9	11
110	The ERA-EDTA Working Group on inherited kidney disorders. Nephrology Dialysis Transplantation, 2012, 27, 67-69.	0.7	10
111	Sudden death due to subarachnoid haemorrhage in an infant with autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2014, 29, iv121-iv123.	0.7	10
112	Spurious hypophosphatemia associated with monoclonal paraproteinemia. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 693-696.	0.5	9
113	Making sense of polycystic kidney disease. Lancet, The, 2017, 389, 1780-1782.	13.7	9
114	An Nphp1 knockout mouse model targeting exon 2â€“20 demonstrates characteristic phenotypes of human nephronophthisis. Human Molecular Genetics, 2021, 31, 232-243.	2.9	9
115	Tubular-derived cytokines and human renal disease progression. Nephrology Dialysis Transplantation, 1994, 9, 471-472.	0.7	8
116	Post-translational modifications of the polycystin proteins. Cellular Signalling, 2020, 72, 109644.	3.6	7
117	Thiazolidinediones inhibit MDCK cyst growth through disrupting oriented cell division and apicobasal polarity. American Journal of Physiology - Renal Physiology, 2011, 300, F1375-F1384.	2.7	6
118	TAMEing ADPKD with metformin: safe and effective?. Kidney International, 2021, 100, 513-515.	5.2	6
119	Surprising new roles for endothelins. BMJ: British Medical Journal, 1996, 312, 195-196.	2.3	6
120	Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't. CKJ: Clinical Kidney Journal, 2022, 15, 1034-1036.	2.9	6
121	â€˜A sword of Damoclesâ€™: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open, 2020, 10, e038005.	1.9	5
122	Effects of noradrenaline infusion on platelet catecholamine levels and platelet aggregation. Journal of Hypertension, 1989, 7, S166-167.	0.5	4
123	Tubulointerstitial actions of endothelins in the kidney: roles in health and disease. Nephrology Dialysis Transplantation, 0, , .	0.7	4
124	Towards the Integration of Genetic Knowledge into Clinical Practice. Nephron Clinical Practice, 2011, 118, c3-c8.	2.3	4
125	Linear and Nonlinear Estimated GFR Slopes in ADPKD Patients Reaching ESRD. American Journal of Kidney Diseases, 2018, 71, 912-913.	1.9	4
126	New onset diabetes after kidney transplantation in patients with autosomal dominant polycystic kidney disease: systematic review protocol: FigureÂ1. BMJ Open, 2015, 5, e008440.	1.9	3

#	Article	IF	Citations
127	Research priorities for autosomal dominant polycystic kidney disease: a UK priority setting partnership. BMJ Open, 2022, 12, e055780.	1.9	3
128	Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study. CKJ: Clinical Kidney Journal, 2022, 15, 2063-2071.	2.9	3
129	Intermittent absorption of warfarin caused by an unrecognized pharyngeal pouch.. Postgraduate Medical Journal, 1989, 65, 660-661.	1.8	2
130	Tuberculous peritonitis complicating peritoneal dialysis: a case for early diagnostic laparotomy?. Nephrology Dialysis Transplantation, 1992, , .	0.7	2
131	A novel dephosphorylationâ€activated conductance in a mouse renal collecting duct cell line. Experimental Physiology, 2009, 94, 914-927.	2.0	2
132	Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone. CKJ: Clinical Kidney Journal, 2021, 14, 1715-1718.	2.9	2
133	Individualized everolimus treatment for tuberous sclerosis-related angiomyolipoma promotes treatment adherence and response. CKJ: Clinical Kidney Journal, 2022, 15, 1160-1168.	2.9	2
134	The Use of Lithium Clearance in Bartter's Syndrome. Nephrology Dialysis Transplantation, 1990, 5, 904-905.	0.7	1
135	Cyst formation in ADPKD: new insights from natural and targeted mutants. Nephrology Dialysis Transplantation, 1999, 14, 544-546.	0.7	1
136	FP064ASSESSING THE LONG TERM OUTCOMES OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) USING THE ADPKD OUTCOMES MODEL: A UK CASE STUDY. Nephrology Dialysis Transplantation, 2015, 30, iii85-iii86.	0.7	1
137	Backbone assignment and secondary structure of the PLAT domain of human polycystin-1. Biomolecular NMR Assignments, 2015, 9, 369-373.	0.8	1
138	FO026GLOBAL MICRORNA PROFILING IN HUMAN URINARY EXOSOMES REVEALS NEW DISEASE BIOMARKERS AND CELLULAR PATHWAYS FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD). Nephrology Dialysis Transplantation, 2019, 34, .	0.7	1
139	Autosomal dominant polycystic kidney disease. , 2015, , 2627-2633.		1
140	Oncogenous hypophosphataemic osteomalacia: effects on phosphate transport and vitamin D metabolism in cultured human kidney cells. Bone, 1995, 16, 679.	2.9	0
141	An unusual complication of pregnancy. Nephrology Dialysis Transplantation, 1999, 14, 1324-1326.	0.7	0
142	Genetic Renal Abnormalities. Medicine, 2003, 31, 32-35.	0.4	0
143	Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells. Journal of Cell Science, 2009, 122, 1702-1702.	2.0	0
144	Structural and Molecular Basis of the Assembly of the TRPP2/PKD1 Complex. Biophysical Journal, 2010, 98, 344a.	0.5	0

#	Article	IF	Citations
145	Whatâ€™s new inâ€¦ Ciliopathies. Medicine, 2011, 39, 119-125.	0.4	0
146	32 PKD2 mutant zebrafish display excessive developmental angiogenesis. Heart, 2011, 97, e7-e7.	2.9	0
147	RENAL DEVELOPMENT AND CYSTIC DISEASES. Nephrology Dialysis Transplantation, 2014, 29, iii73-iii78.	0.7	0
148	Development Of A Model To Predict Disease Progression In Autosomal Dominant Polycystic Kidney Disease (ADPKD). Value in Health, 2014, 17, A564.	0.3	0
149	SuO042POLYCYSTIN-1 TRAFFICKING IS REGULATED BY CAMP DEPENDENT PHOSPHORYLATION OF THE PLAT DOMAIN. Nephrology Dialysis Transplantation, 2015, 30, iii63-iii63.	0.7	0
150	FP364INCREASED PSYCHOSOCIAL BURDEN AND ADVERSE QUALITY OF LIFE IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2015, 30, iii190-iii190.	0.7	0
151	SO052DEVELOPMENT OF A RAPID SEMI-AUTOMATED TOOL TO MEASURE TOTAL KIDNEY VOLUME IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2016, 31, i22-i22.	0.7	0
152	SO053SELECTIVE PROSTAGLANDIN E2 RECEPTOR BLOCKADE FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2016, 31, i22-i23.	0.7	0
153	The Cyclic AMP Signaling Pathway and Direct PKA Phosphorylation Regulate Polycystin-2 (TRPP2) Channel Function. Biophysical Journal, 2016, 110, 611a-612a.	0.5	0
154	Development of a rapid semi-automated tool to measure total kidney volume in autosomal dominant polycystic kidney disease. Lancet, The, 2017, 389, S90.	13.7	0
155	TO033VERY EARLY-ONSET AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE DUE TO BI-ALLELIC MUTATIONS IN PKD1 AND PKD2. Nephrology Dialysis Transplantation, 2017, 32, iii94-iii94.	0.7	0
156	SAT-100 â€œA SWORD OF DAMOCLESâ€• PATIENT AND CAREGIVER BELIEFS, ATTITUDES AND PERSPECTIVES ON GENETIC SCREENING AND TESTING FOR AUTOSOMAL POLYCYSTIC KIDNEY DISEASE - FOCUS GROUP STUDY. Kidney International Reports, 2019, 4, S48.	0.8	0
157	SAT-334 GENETIC TESTING OF FAMILIES WITH VERY EARLY ONSET POLYCYSTIC KIDNEY DISEASE REVEALS THE FUNCTIONAL SIGNIFICANCE OF HYPOMORPHIC VARIANTS. Kidney International Reports, 2019, 4, S148.	0.8	0
158	SaO005CLINICAL PRESENTATION AND PROGNOSIS OF DNAJB11-ASSOCIATED NEPHROPATHY: AN INTERNATIONAL COLLABORATIVE STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
159	SAT-442 Identification of Exosome MicroRNAs as Novel Biomarkers for Rapid Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2020, 5, S185.	0.8	0
160	SO092REDUCED QUALITY OF LIFE IN ADPKD PATIENTS WITH CKD STAGE 1-3: THE CYSTIC I QUALITY OF LIFE STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
161	MO023FLANK PAIN HAS A MAJOR NEGATIVE IMPACT ON HEALTH-RELATED QUALITY OF LIFE IN ADPKD: THE CYSTIC I STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
162	Screening for intracranial aneurysms in ADPKD. BMJ: British Medical Journal, 2009, 339, b4204-b4204.	2.3	0

#	Article	IF	Citations
163	TRPP2 in Polycystic Kidney Disease. , 2014, , 491-522.		0
164	Genetics and Genomics of Chronic Kidney Disease. , 2014, , 369-392.		0
165	Autosomal dominant polycystic kidney disease. , 2015, , 2625-2626.		0
166	Imaging of kidney cysts and cystic kidney diseases in children. Consensus paper by an ad hoc committee. Ultraschall in Der Medizin, 2018, 39, .	1.5	0
167	FC029: A Multivariate Model Identifies Genotype, Hypertension and Kidney Length as Independent Baseline Predictors of Disease Progression in a Longitudinal Autosomal Dominant Polycystic Kidney Disease Patient Cohort. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
168	MO030: Familial clustering of a rare UMOD variant in undiagnosed hereditary nephropathy suggests the presence of a common ancestral founder mutation. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
169	MO015: The Interaction of Gender and Genotype in the Development of Polycystic Liver Disease in ADPKD. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0